ReviewWorld journal of surgical oncology2025
Retrospective analysis of diffuse large B-cell lymphoma treated with the R-CHOP regimen at a Malaysian tertiary hospital.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Characteristics and Prognostic Factors of Primary Bone Diffuse Large B-Cell Lymphoma: A Retrospective Study.Cancer medicine · 2026Article
- A deep learning-based prognostic model for diffuse large B-cell lymphoma incorporating PET/CT imaging features.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), is an aggressive malignancy and the most prevalent subtype of lymphoma both globally and in Malaysia. This study aimed to assess the clinical course, treatment response to the R-CHOP regimen (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone), and survival outcomes of patients diagnosed with DLBCL at a tertiary care center.
methodsA retrospective analysis was conducted on patients diagnosed with de novo DLBCL between 2015 and 2020. Demographic profiles, clinical features, treatment information, and outcomes were systematically collected and evaluated.
resultsA total of 202 patients were analyzed, with a median age of 58 years (interquartile range: 20). The majority were male (58.4%). The median follow-up period was 50.1 months (interquartile range: 64.6). All patients received at least one cycle of the R-CHOP regimen. Following chemotherapy, 6.9% of patients underwent radiotherapy as a consolidative approach. A complete response was achieved in 57.9% of cases. The three-year overall survival (OS) and progression-free survival (PFS) rates were 60.9% and 58.4%, respectively. Patients with higher International Prognostic Index scores demonstrated significantly poorer OS and PFS than those with lower scores (p < 0.0001 for both). The presence of B symptoms was also associated with inferior OS and PFS (p = 0.047 and 0.044, respectively). Furthermore, hypoalbuminemia (serum albumin < 35 g/L) emerged as an independent prognostic indicator linked to reduced OS in multivariate analysis (p = 0.0040).
conclusionsThis study provides key insights into the clinical characteristics and treatment outcomes of Malaysian patients with DLBCL managed with the R-CHOP regimen. Age, presence of B symptoms, disease stage, baseline serum albumin, and lactate dehydrogenase levels were identified as significant prognostic markers that may help predict survival in newly diagnosed DLBCL cases. Larger, prospective trials with prolonged follow-up are necessary to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.